Phaseline

Targets › RECA

RECA (DNA repair protein RAD51 homolog 1): drug programs, companies and trials

1 program from 1 company in 1 trial: 1 Phase 3; Infectious disease; next expected readout Mar 2027.

Homologous DNA recombinase that catalyzes strand exchange, a key step in DNA repair through homologous recombination (HR). Binds to single-stranded DNA (ssDNA) in an ATP-dependent manner to form nucleoprotein filaments which are essential for the homology search and strand exchange. (UniProt, Q06609)

Open in Phaseline: the race on RECA, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Institute of Tropical Medicine, Belgiumbedaquiline
ATP synthase inhibitor
RECAPhase 3LeprosyMar 2027

Conditions

Leprosy (1)

Modalities

small molecule (1)

Companies

Institute of Tropical Medicine, Belgium (1)

Related targets

–

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.